How Much Practical Cure Research Do the Major Type 1 Non-Profits Fund? by Peter Miselis
  
Conclusions:       
 
 The  PracƟcal  Cure  research  that  the  four  major  non-proﬁts  funded  on  a  com-­‐
bined  basis  in  2012  amounted  to  just  2%  of  total  donor  contribuƟons,  with  the  
remaining  98%  of  contribuƟons  used  for  other  types  of  research  and  non-
research  acƟviƟes. 
 
 JDRF  and  the  DRIF  were  the  largest  funders  of  PracƟcal  Cure  research  in  2012,  at  
$6  million  and  $3  million,  respecƟvely.  The  ADA  and  Joslin  funded  no  PracƟcal  
Cure  research.     
 
 Nine  out  of  ten  donors  prefer  to  fund  PracƟcal  Cure  research  over  Idealized  Cure  
research,  yet  the  overall  allocaƟon  to  PracƟcal  Cure  research  does  not  reﬂect  this  
wish.                 
 
 The  non-proﬁts  and  the  donor  community  both  have  the  ability  to  meaningfully  
increase  PracƟcal  Cure  funding.  The  non-proﬁts  can  establish  a  PracƟcal  Cure  ini-­‐
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The  JDCA  and  its  employees  seek  to  maintain  independence  from  organizaƟons  covered  in  its  research  reports.    The  JDCA  and  its  employees  are  free  from  
conﬂicts  of  interest,  receive  no  compensaƟon  from  the  organizaƟons  discussed  in  its  reports,  and  seek  to  avoid  any  relaƟonships  with  any  organizaƟons  that  
could  inﬂuence  its  objecƟvity  and  independence.    Please  see  Analyst  CerƟﬁcaƟon  and  Other  Disclosures  at  the  end  of  this  report 
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This  report  quanƟﬁes  the  major  type  1  non-proﬁts’  funding  for  PracƟcal  Cure  research.  Our  key  ﬁnding  is  that  the  four  
major  non-proﬁts  combined  allocated   just   two  cents  of  every  donor  dollar   to  PracƟcal  Cure   research   in  2012.  The  
remaining  ninety-eight  cents  of  every  donor  dollar  were  used  to  fund  other  types  of  research  and  non-research  acƟvi-­‐
Ɵes.  This  allocaƟon  is  inconsistent  with  donors’  wish  to  have  PracƟcal  Cure  research  well-funded. 
 
We  will  break  down  the  ninety-eight  cents  of  every  donor  dollar  that  is  not  directed  to  PracƟcal  Cure  research  to  evalu-­‐
ate  how  donor  contribuƟons  are  being  used  at  each  of  the  four  non-proﬁts.  We  also  oﬀer  suggesƟons  to  beƩer  align  
donor  interests  with  how  their  contribuƟons  are  spent.           
 
In  assembling  the  data,  the  JDCA  examined  the  abstracts  for  over  550  individual  research  project  that  were  funded  in  
2012.  The  JDRF  and  ADA  make  abstracts  for  nearly  all  of  their  type  1  projects  publicly  available  on  their  websites.  The  
DRIF  and  Joslin  do  not  make  abstracts  for  individual  research  projects  publicly  available.  In  the  case  of  the  DRIF,  we  ob-­‐
tained  and  reviewed  informaƟon  on  their  2012  projects  from  management  and  the  Diabetes  Research  InsƟtute.  Joslin  
declined  to  provide  any  such  informaƟon. 
   
 
How  much  was  donated  to  the  four  non-proﬁts  and  how  much  was  allocated  to  type  1  research? 
 
This   secƟon  examines  donors’   generous   contribuƟons   to   the  major  diabetes  non-proﬁts   and   the  non-proﬁts’   alloca-­‐
Ɵons  to  type  1  research.  The  table  in  Exhibit  A  illustrates  select  funding  data  for  the  non-proﬁts  in  2012.   
 













                                                                 
                       
Source:  Charity  and  FoundaƟon  data.  JDCA  Research.  The  ADA’s  ﬁnancial  statements  for  2012  have  not  yet  been  published;  ADA  
Donor  ContribuƟons  and  All  Other  Type  1  Research  are  JDCA  esƟmates  based  on  2012  data  being  ﬂat  with  2011.  DRIF’s  actual  
Donor  ContribuƟons   for  2012  were  $7  million.  However,   this  ﬁgure   is  adjusted  upward  to  $11  million  because  DRIF  funded  $4  
million  of   its  2012  operaƟng  budget  from  a  reducƟon   in   its  net  asset  posiƟon.  This  $4  million  originated  with  donor  contribu-­‐
Ɵons.  Therefore,  the  $11  million  ﬁgure  is  a  more  accurate  representaƟon  of  donor  contribuƟons  used  to  fund  research.  Joslin’s  
All  Other  Type  1  Research  is  a  JDCA  esƟmate  arrived  at  by  assuming  that  40%  of  its  Total  Research  budget  is  directed  to  type  1  
and  60%  to  type  2,  similar  percentages  that  Joslin  provided  for  2010,  the  most  recent  year  for  which  the  JDCA  has  data. 
 
As  seen  in  Table  A,  allocaƟons  to  PracƟcal  Cure  research  in  2012  totaled  $9  million,  or  just  2%  of  total  donor  contri-­‐
buƟons  to  the  four  major  non-proﬁts  combined.  The  funding  and  prioriƟzaƟon  of  PracƟcal  Cure  research  varied  signiﬁ-­‐
cantly  by  organizaƟon,  and  our  analysis   indicates  that  only  two  of  the  four  organizaƟons,  the  DRIF  and  JDRF,  funded  
PracƟcal  Cure  work  last  year.     
 
Ninety-eight  percent  of  donor  contribuƟons  were  directed  to  funding  other  categories  of  type  1  research  in  addiƟon  to  
acƟviƟes  other  than  type  1  research.  Funding  for  research  in  all  other  major  categories  signiﬁcantly  exceeded  the  sup-­‐
port  for  PracƟcal  Cure  research.  Please  see  Appendix  A  on  page  6  for  a  more  detailed  breakdown  of  type  1  research  
funding  broken  down  into  key  categories  for  each  non-proﬁt  . 






All Other Type 1 
Research $
Practical Cure 
Research as % 
Donor 
Contributions
ADA $160 $0 $13 0%
DRIF 11 3 4 27%
JDRF 196 6 104 3%
Joslin 13 0 13 0%
Total $380 $9 $134 2%
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PracƟcal  Cure  vs.  Idealized  Cure  funding  represents  a  disconnect 
 
It  is  important  to  make  the  disƟncƟon  between  the  two  primary  types  of  cure  research,  PracƟcal  and  Idealized.  A  pri-­‐
mary  diﬀerence  between   Idealized  Cure  and  PracƟcal  Cure  research   is  whether   the  research   is  designed  to  deliver  a  
cure  for  type  1  in  the  foreseeable  future. 
 
 PracƟcal  Cure  research   is  deﬁned  by  outcomes  that  would  provide  a  “like  normal”  lifestyle  to  individuals  who  are  
currently   living  with   type   1.   Importantly,   PracƟcal   Cure   projects   have   the   potenƟal   to   deliver   the   targeted  out-­‐
comes  by  a  Ɵme  goal  in  the  foreseeable  future.  Please  see  Appendix  B  on  page  6  for  a  more  detailed  explanaƟon.   
 
 Idealized  Cure  research  encompasses  many  areas  and  types  of  research  that  on  their  own  are  unlikely  to  deliver  a  
cure  within  the  foreseeable  future.  Please  see  Appendix  C  on  page  7  for  a  more  complete  descripƟon  of  the  diﬀer-­‐
ent  types  of  Idealized  Cure  research.   
 
The   chart   in   Exhibit   B   compares   the   combined   allocaƟons   that   three   of   the   four   non-proﬁts   (ADA,   DRIF,   and   JDRF)  
made  to  PracƟcal  Cure  research,  Idealized  Cure  research  and  all  other  categories  of  type  1  research  in  2012. 
 
 
















                                                                                                                     
 
                                                            Source:    Charity  and  FoundaƟon  data  for  ADA,  DRIF,  JDRF;  JDCA  Research 
 
 
The  fact  that  funding  for  PracƟcal  Cure  research  was  dwarfed  by  the  allocaƟons  to  Idealized  Cure  research  and  to  all  
other  types  of  type  1  research  for  the  three  non-proﬁts  combined  last  year  represents  a  gross  disconnect  with  donor  
preferences.  JDCA  research  indicates  that  9  out  of  10  donors  strongly  prefer  PracƟcal  Cure  research  over  Idealized  Cure  
research.1    Yet  the  funding  for  these  two  categories  in  2012  was  heavily  weighted  in  the  opposite  direcƟon,  as  Idealized  
Cure  research  received  $59  million  in  funding  compared  with  $9  million  for  PracƟcal  Cure.   
 
Comparing  the  $9  million  in  funding  for  PracƟcal  Cure  research  to  the  $121  million  allocated  to  all  other  type  1  re-­‐
search  is  even  more  striking.  This  proporƟonately  low  level  of  support  for  PracƟcal  Cure  research  is  inconsistent  with  
donor  prioriƟes  as  an  overwhelming  85%  of  donors  believe  that  PracƟcal  Cure  research   is  either  very  valuable  or  ex-­‐
tremely  valuable.2 
 
















The  allocaƟon  of  funds  for  research  and  non-research  purposes 
 
The  charts  in  Exhibit  C  depict  the  organizaƟons’  funding  for  research  and  non-research  acƟviƟes,  with  research  acƟvi-­‐
Ɵes  divided   into  the   following  categories:  PrevenƟon,  ComplicaƟons,  Glucose  Control,   Idealized  Cure,  PracƟcal  Cure,  
and  Type  2  Diabetes.   
 
Exhibit  C:  2012  AllocaƟon  of  Total  OperaƟng  Expenses 
 





                                                                                                                                   







                                                                                           
















Source:  Charity  and  FoundaƟon  data;  JDCA  Research 
 
Exhibit  C  Summary  ObservaƟons 
 
 JDRF’s  allocaƟon  of  $6  million  to  PracƟcal  Cure  research  made  it  the  largest  funder  in  dollars,  exceeding  the  DRIF’s  
$3  million  allocaƟon.  The  ADA  and  Joslin  funded  no  PracƟcal  Cure  research  in  2012.   
 The  vast  majority  of  cure  research  is  Idealized,  which  is  highly  unlikely  to  deliver  a  cure  by  2025. 
 Funding   for  non-research  acƟviƟes   (which  may   include  overhead,   fundraising,  educaƟon,  awareness,  and  clinical  
care)  is  the  single  largest  category  for  every  non-proﬁt.  It  is  important  that  the  commitment  to  these  acƟviƟes  does  
not  divert  resources  away  from  PracƟcal  Cure  research. 
 AddiƟonal  details  of  the  research  budgets  for  the  ADA  and  JDRF  can  be  seen  in  Appendix  D  on  page  8,  which  breaks  
down  research  spending  into  sub-categories.   










































Note:  the  DRIF’s  
research  funding  
represents  roughly  
one-half  of  the  




The  JDCA  believes  that  an  equitable  allocaƟon  of  donor  contribuƟons  would  represent  the  intenƟons  of  donors  as  well  
as  the  messaging  that  is  used  to  solicit  donaƟons.  There  is  a  moral  imperaƟve  for  the  non-proﬁts  to  recognize  the  inter-­‐
est  of  all  stakeholders  and  fund  the  acƟviƟes  that  are  important  to  them.     
 
The  key  point  in  the  current  funding  situaƟon  is  that  most  of  the  major  non-proﬁts  do  not  prioriƟze  PracƟcal  Cure  
research  despite  the  facts  that  donors  highly  value  it  and  the  type  1  cure  promise  is  heavily  relied  upon  in  fundrais-­‐
ing  messaging.3  Donors  who  favor  PracƟcal  Cure  research  are  underrepresented   in   the  allocaƟon  of  donor  contribu-­‐
Ɵons  for  most  of  the  non-proﬁts.  PracƟcal  Cure  research  receives  the  least  funding  of  all  major  spending  areas  and  is  
dwarfed  by   Idealized  Cure   funding.   Yet  donors  have  an  overwhelming  preference   for  PracƟcal  Cure   research,  which  
results  in  a  gross  inconsistency  between  what  donors  want  and  how  their  contribuƟons  are  actually  used.     
 
 
What  can  be  done? 
 
SoluƟons  can  be  easily  implemented  to  directly  address  inconsistencies  in  the  use  of  donaƟons  by  making  a  greater  
commitment   to   PracƟcal   Cure   work.   The  non-proﬁts   can   implement   speciﬁc   steps   to  establish   a   PracƟcal   Cure   re-­‐
search  iniƟaƟve  which  would  involve:   
 
 Deﬁning  speciﬁc  PracƟcal  Cure  outcomes  and  seƫng  a  Ɵme  goal  to  focus  research  eﬀorts  and  create  urgency 
 Determining  which  projects  have   the  potenƟal   to  deliver   the   targeted  outcomes  and   implemenƟng  objec-­‐
Ɵves  to  tangibly  measure  progress  along  the  way       
 Developing  the  prioriƟzed  projects  by  fully  funding  them  and  communicaƟng  progress  with  stakeholders 
 Delivering  results  by  ensuring  that  the  best  projects  are  fast-tracked  to  human  trials 
 
Donors  also  play  a  crucial  role  in  funding  PracƟcal  Cure  research.  The  easiest,  most  direct  way  to  make  an  impact    is  to  
sƟpulate  that  your  donaƟon  be  used  only  for  PracƟcal  Cure  research.  The  JDCA  provides  tools  to  guide  donors’  giving  
decision,  ranging  from  a  SƟpulaƟon  LeƩer  that  can  be  aƩached  to  your  donaƟon  to  a  Donor  Giving  Guide  that  can  be  
used  to  structure  a  more  complex  philanthropic  relaƟonship  with  your  preferred  charity  or  foundaƟon.  These  tools  can  
be  accessed  on  the  JDCA  website  at:  hƩp://www.thejdca.org/donor-page/.   
 
 
Summary  and  Conclusions 
 
AŌer  an  extensive  examinaƟon  of   research  projects  that  were   funded  by  the  major  non-proﬁts   in  2012,  we  have  
concluded  that  PracƟcal  Cure  research   is  clearly  not  a  priority   for  most  of   the  non-proﬁts.  Our  research   indicates  
that  PracƟcal  Cure  research  received  very  limited  funding  in  2012,  an  extremely  small  2%  of  total  donor  contribu-­‐
Ɵons  for  the  four  major  chariƟes  combined.  Only  the  DRIF  and  JDRF  funded  PracƟcal  Cure  projects  last  year,  accord-­‐
ing   to   our   analysis.   Funding   for   PracƟcal   Cure   research   as   a   percentage   of   donor   contribuƟons  was   signiﬁcantly  
greater  for  the  DRIF  than  JDRF.  The  ADA  and  Joslin  provided  no  PracƟcal  Cure  funding. 
 
An  important  disconnect  exists  between  the  non-proﬁts’  use  of  contribuƟons  and  what  donors  view  as  important.  
Although  donors  overwhelmingly  prefer  PracƟcal  Cure  research  over  Idealized  Cure  research,  the  non-proﬁts’  allo-­‐
caƟons  to  other  types  of  research  and  non-research  acƟviƟes  far  outweigh  the  amounts  directed  to  PracƟcal  Cure  
projects.     
 
Both  the  non-proﬁts  and  donors  can  iniƟate  acƟon  steps  to  meaningfully  close  this  gap.  Every  non-proﬁt  could  im-­‐
plement  a  PracƟcal  Cure  research  iniƟaƟve  that  would  prioriƟze  this  type  of  work  and  direct  more  resources  to  it.    
AlternaƟvely,  donors  themselves  can  be  instrumental  in  increasing  funding  for  PracƟcal  Cure  research  by  sƟpulaƟng  
that  their  donaƟon  only  be  used  for  this  purpose.   
How Much Practical Cure Research Do the Major Type 1 Non-Profits Fund? 
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Appendix  A:  Type  1  Research  Funding  for  2012  ($  Mil.) 
Source:  Charity  and  FoundaƟon  data.  JDCA  Research.  The  ADA’s  ﬁnancial  statements  for  2012  have  not  yet  been  published.  The   total  type  1  re-­‐
search  ﬁgure  assumes  that  2012  spending  was  ﬂat  with  2011.  The  ADA’s  individual  research  category  ﬁgures  are  percentages  based  on  the  $13  
million  of  total  type  1  spending.  Joslin’s  $13  million  for  total  type  1  research  is  arrived  at  by  assuming  that  40%  of  its  Total  Research  budget  of  $32  










Appendix  B:  PracƟcal  Cure  Outcomes 
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 Does not require blood glucose 
monitoring beyond once a week
 A1C levels 5-7%
 Does not restrict  a  patient’s  diet
 Does not require carb counting
 Allows patients to sleep care free
 Best case:  Zero side effects
 Acceptable case: Insignificant  
side effects
 If surgical, less  than 72 
hours recovery





Minimal Side Effects 






Total Type 1 
Research Non-Research
ADA 0 4 1 3 5 13 187
DRIF 3 3 0 1 0 7 4
JDRF 6 52 13 17 22 110 95
Joslin 0 NA NA NA NA 13 73
Total 9 59 14 21 27 143 359
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Appendix  C:  Idealized  Cure  Research 
 
The  following  is  a  more  detailed  descripƟon  of  the  Idealized  Cure  sub-categories.  Joshua  Levy,  is  an  independent  ob-­‐
server  of  the  type  1  landscape.  His  contribuƟons  helped  to  determine  the  composiƟon  of  these  subcategories.   
 
At  a  basic  level,  a  cure  for  type  1  diabetes  would  provide  a  source  of  insulin  that  responds  to  changes  in  blood  glucose  
in  real  Ɵme,  and  protect  that  source  from  aƩack  by  the  immune  system.  Developing  components  of  a  cure  in  isolaƟon  
signiﬁcantly  increases  the  amount  of  Ɵme  required  to  put  the  pieces  together.  Therefore,  any  research  project  that  did  
not  ulƟmately  endeavor  to  deliver  all  components  of  a  PracƟcal  Cure  by  2025  was  classiﬁed  as   Idealized  rather  than  
PracƟcal  Cure  research.   
 
The  ﬁrst  three  sub-categories  have  to  do  with  restoring  insulin  producƟon  in  the  body:   
 1)  Cell  supply: 
 beta  cell  reprogramming:  changing  one  type  of  fully  developed  cell  into  an  insulin-producing  beta  
cell 
 beta  cell  programming:  making  an  undiﬀerenƟated  stem  cell  become  an  insulin-producing  beta  cell 
 donor  cells:  obtaining  insulin-producing  beta  cells  from  an  exogenous  source 
                              2)  Beta  cell  growth:  expanding  the  mass  or  insulin-producing  ability  of  beta  cells 
   
The  next  two  sub-categories  have  to  do  with  keeping  the   insulin-producing  cells  safe   from   immune  system  aƩack   in  
one  of  two  ways:   
 3)  Immune  modiﬁcaƟon:  altering  the  immune  system  by  halƟng  the  immune  response  that  kills  beta  cells,  or  
 by  teaching  the  immune  system  not  to  aƩack  in  the  ﬁrst  place   
 4)  Immune  protecƟon:  hiding  the  beta  cells  from  the  immune  system  aƩack 
 
AddiƟonal  subcategories  of  Idealized  Cure  research  include: 
 5)  Basic  and  Exploratory:  invesƟgaƟng  essenƟal  aspects  of  how  diabetes  works,  its  causes  and  progression   
 6)  Research   Tools   and   Techniques:  developing  material   to  be  used   in  experiments   (e.g.  geneƟcally  modiﬁed  
 mice)  or  equipment  with  which  to  conduct  experiments  (e.g.  imaging  systems  to  measure  beta  cell  mass)   
7)  Orphaned  projects  are  not  PracƟcal  Cure  projects  by  themselves.  If  they  were  combined  with  other  potenƟal  
PracƟcal  Cure  projects  then  together  that  research  could  be  categorized  as  PracƟcal  Cure  research.  Islet  trans-­‐
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Appendix  D:  Breakdown  of  Type  1  Research 
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The JDCA analyst responsible for the content of this report certifies that with respect to each organization 
covered in this report: 1) the views expressed accurately reflect his own personal views about the organiza-
tions; and 2) no part of his compensation was, is, or will be, directly or indirectly, related to the specific views 
expressed in this research report. 
 
Other Disclosures 
All Rights Reserved. The JDCA and its employees will not be liable for any claims or lawsuits from any third 
parties arising from the use or distribution of this document. This report is for distribution only under such 
circumstances as may be permitted by applicable law.  
All information expressed in this document was obtained from sources believed to be reliable and in good 
faith, but no representation or warranty, express or implied, is made as to its accuracy or completeness. All 
information and opinions are current only as of the date of this report and are subject to change without 
notice. 
